Table 1

Summary of results for HRSV F mutations.
Mutation
 Processing
 Percent binding
 Fusion activity


ch101F
 palivizumab
 mAb19
Wild-type
 Complete
 99.9
 100.0
 99.9
 1.0 ± 0.0
K272M
 Complete
 126.6
 3.8
 100.5
 2.3 ± 0.7
K272N
 Complete
 95.5
 15.3
 62.3
 2.2 ± 0.5
K272Q
 Complete
 85.3
 30.1
 88.7
 2.6 ± 0.1
K272T
 Complete
 70.4
 9.1
 68.0
 1.0 ± 0.1
S275F
 Complete
 29.4
 10.9
 31.7
 1.6 ± 0.2
T400A
 Complete
 155.2
 126.6
 161.2
 2.9 ± 0.5
C422S
 Complete
 159.6
 177.5
 193.9
 1.6 ± 0.6
N428D
 Complete
 116.2
 139.4
 121.3
 0.75 ± 0.02
N428Q
 Complete
 117.2
 190.2
 193.8
 1.5 ± 0.02
R429K
 Complete
 44.6
 88.8
 11.2
 4.0 ± 0.2
R429S
 Complete
 72.5
 150.0
 3.9
 1.1 ± 0.1
G430A
 Complete
 79.7
 166.5
 0.15
 1.2 ± 0.2
I431A
 Complete
 61.9
 108.2
 81.8
 1.6 ± 0.3
I431L
 Complete
 78.5
 80.9
 65.5
 1.8 ± 0.1
I432L
 Complete
 74.9
 68.9
 64.4
 1.5 ± 0.2
I432Q
 Complete
 49.3
 60.8
 57.9
 0.7 ± 0.07
I432T
 Complete
 191.7
 206.9
 169.8
 1.4 ± 0.3
K433D
 Complete
 1.1
 29.9
 1.6
 0.4 ± 0.01
K433L
 Complete
 3.8
 88.1
 24.5
 0.5 ± 0.1
K433N
 Complete
 2.9
 80.7
 28.7
 2.2 ± 0.5
K433Q
 Complete
 2.7
 60.7
 47.4
 1.0 ± 0.8
K433R
 Complete
 -0.6
 15.8
 23.1
 2.0 ± 0.6
K433T
 Complete
 3.9
 64.5
 64.4
 0.6 ± 0.04
K433S
 Complete
 69.5
 86.3
 111.8
 0.98 ± 0.19

Processing is defined as relative amounts of F0, F1, and F2, and is described as being equivalent to wild-type HRSV F protein (complete) or reduced. Reactivity with neutralizing mAbs (palivizumab, Mab19, and ch101F) as determined by flow cytometry is reported as percent relative to wild-type HRSV F protein. Cell fusion activity (luciferase activity) is reported relative to wild-type as described in [30]. All values are expressed as relative to wild-type.

Liu et al. Virology Journal 2007 4:71   doi:10.1186/1743-422X-4-71